


## Introduction

- Hypertension in children is a growing problem.
- Multifactorial in origin.
- Hypertensive children, although usually asymptomatic, already manifest evidence of target organ damage. Up to $40 \%$ of hypertensive children have left ventricular hypertrophy and hypertensive children have increased carotid intima-media thickness, a marker of early atherosclerosis.
- Primary hypertension during childhood often tracks into adulthood. Children with BP >90th percentile have a 2.4-fold greater risk of having hypertension as adults. Similarly, nearly half of hypertensive adults had a BP >90th percentile as children. There is also an association between childhood hypertension and early atherosclerosis in young adulthood.
- Early intervention prevents development and progression of target organ damage.


## Definition

- The definition of hypertension in adults is $B P \geq 140 / 90 \mathrm{~mm} \mathrm{Hg}$, regardless of body size, sex, or age. This is a functional definition that relates level of BP elevation with the likelihood of subsequent cardiovascular events.
- The definition of hypertension in children is statistical rather than functional. It includes normal values based on the normative distribution of BP in healthy children and tables with systolic and diastolic values for the 50th, 90th, 95th, and 99th percentile by age, sex, and height percentile.


## Definition

- So, hypertension is defined as Average systolic blood pressure (SBP) and/or diastolic $B P$ that is $\geq 95$ th percentile for age, sex, and height on $\geq 3$ occasions.
Adolescents $\geq 13$ y/o with BP $\geq 130 / 80$ are considered to be hypertensive.
- Prehypertension is defined as average SBP or diastolic BP that are $\geq 90$ th percentile but $\leq 95$ th percentile in a medical setting but normal BP outside of the office has white coat hypertension.
Adolescents $\geq 13 \mathrm{y}$ /o with BP levels greater than or equal to $120 / 80 \mathrm{mmHg}$ should be considered to have elevated BP (prehypertension).


## Definition

- Studies further recommended that if BP is $\geq 95$ th percentile, then the hypertension should be staged.
- Children with BP between the 95th and 99th percentile plus 5 mm Hg are categorized as stage 1 hypertension
- And children with BP above the 99th percentile plus 5 mm Hg have stage $\mathbf{2}$ hypertension.
- Stage 1 hypertension, if asymptomatic and without target organ damage, allows time for evaluation before starting treatment, whereas stage 2 hypertension calls for more prompt evaluation and pharmacologic therapy.


## Classification of blood pressure in children and adolescents

| Table 166-1 | Classification of Blood Pressure |
| :--- | :--- |
| BLOOD PRESSURE | BLOOD PRESSURE |
| CATEGORY | PERCENTILE (\%) |
| Normal | $<90$ th |
| Prehypertension | '90th to 95 th |
| Stage 1 hypertension | 95 th to ( $99 \mathrm{th}+5 \mathrm{~mm} \mathrm{Hg})$ |
| Stage 2 hypertension | $>99 \mathrm{th}+5 \mathrm{~mm} \mathrm{Hg}$ |

*If 90 th $\%$ is $>120 / 80$, use $120 / 80$ as the lower limit.

# Classification of blood pressure in Pediatrics up to 12 years old 

| Age | $\mathrm{SBP}(\mathrm{mm}$ of Hg$)$ | $\mathrm{DBP}(\mathrm{mm}$ of Hg$)$ |
| :--- | :---: | :---: |
| Newborn | $50-70$ | $25-45$ |
| $6 \mathrm{mths}-1 \mathrm{yr}$ | $60-90$ | $50-70$ |
| $1-6 \mathrm{yrs}$ | $70-100$ | $40-50$ |
| $7-12 \mathrm{yrs}$ | $90-110$ | $50-70$ |

# Classification of blood pressure in Children 13 years and older 

For Children Aged $\geq 13 \mathrm{y}$
Normal BP: <120/<80 mm Hg Elevated BP: $120 /<80$ to $129 /<80 \mathrm{~mm} \mathrm{Hg}$

Stage 1 HTN: 130/80 to 139/89 mm Hg

Stage 2 HTN: $\geq 140 / 90 \mathrm{~mm}$ Hg

## Classification of blood pressure in Boys

Blood Pressure Levels for Boys by Age and Height Percerntile

| Arom | $\stackrel{\operatorname{sen}}{\text { Perognse }}$ |  |  |  |  |  |  |  | Oxastatic ssp (mameva) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $\leftarrow$ |  | Percemsite af nelolat $\rightarrow$ |  |  |  |  | $\leftarrow$ Percemsite of nrelyme $\rightarrow$ |  |  |  |  |  |  |
|  |  | Ser | soms | 2smb | soun | 7 rew | soen | S5en | Sem | sots | 25sh | sorm | 7nets | soun | 95xh |
| * | 50m | 80 | 83 | 83 | as | 87 | 80 | Os | 36 | 35 | 36 | 37 | 30 | 39 | 39 |
|  | som | 30 | as | 37 | 90 | voo | 100 | 103 | 49 | so | 50 | 52 | 53 | 53 | 54 |
|  | 95un | 30 | 90 | no* | 100 | vos | 106 | voe | 54 | 54 | Ss | Se | 57 | se | Se |
|  | som | 305 | Tos | тow | 110 | 182 | 123 | 134 | 61 | 62 | 63 | Es | 65 | -6 | 6s |
| 2 | soms | 3 | \%s | 87 | 88 | $\infty$ | 32 | $\infty$ | 30 | 40 | 4 | 43 | 43 | - 2 | 4 |
|  | sous | 37 | 90 | *00 | 100 | vos | 10s | +00 | 5 | so | se | 57 | se | se | so |
|  | asm | งอง | vea | vos | vos | voe | 100 | 110 | so | so | $\infty$ | ev | E2 | es | 03 |
|  | 990n | nos | T10 | \%17 | $1 \times 3$ | 173 | 127 | 17 | se | er | $\cdots$ | 0 | 70 | 7 | 70 |
| 3 | sonk | me | 87 | 89 | 9 | 93 | 94 | 93 | 44 | 4 | 45 | * | 47 | * | 48 |
|  | somm | 100 | 10\% | 209 | vos | vo7 | 10e | 200 | 59 | 59 | $\cdots$ | ET | E2 | es | *3 |
|  | 95en | Noe | Tos | vor | 109 | 170 | 112 | 113 | 63 | 63 | © | 6s | ec | 67 | 67 |
|  | 9omm | 121 | 172 | 17* | 120 | 17e | 110 | 220 | 77 | 71 | 72 | 73 | 74 | TS | 75 |
| * | Som | 8 | 68 | $0 \%$ | 93 | Os | 96 | 97 | 47 | 48 | 4 | so | 57 | 57 | 52 |
|  | som | voz | sas | sos | vor | 100 | N20 | 121 | 62 | 63 | 5\% | 55 | 56 | © | 6) |
|  | asen | voe | *e7 | 200 | ** | 122 | 1.4 | v* | - | 6\% | -8 | -9 | 70 | 7 | 71 |
|  | soen | 13 | 174 | T ข | No | 120 | 12\% | 122 | 74 | 75 | 76 | 75 | 78 | Je | 70 |
| $s$ | som | 9 | 9 | 93 | 95 | Se | ง® | $\infty$ | so | 5 | 52 | 53 | 54 | 55 | 55 |
|  | som | vos | vos | voe | vos | * 2 | ** | 112 | es | - | 67 | 50 | 69 | 09 | 70 |
|  | asen | voe | sos | vo | 182 | 114 | 115 | ve | es | 70 | 70 | 72 | 73 | 7 | 70 |
|  | asen | 175 | ขve | T 1 | 120 | 127 | 123 | 123 | 77 | 7e | 73 | -0 | อง | as | 82 |
| © | Som | 97 | 92 | \% | 9 | 9 | 90 | 100 | 53 | 53 | 5 | ss | Se | 57 | 57 |
|  | soen | vas | ข06 | vos | vo | 20\% | 123 | 113 | 68 | ce | 00 | 70 | 77 | 72 | 32 |
|  | asen | voe | $1 \times$ | 122 | *** | v*s | v7 | ** | 72 | 72 | 73 | 70 | 75 | 70 | re |
|  | som- | \% 1 * | 177 | 170 | *2* | 123 | v2a | 12s | no | -0 | 8\% | ex | 3 | es | E4 |
| 7 | soun | 92 | 93 | 9s | 97 | - | N00 | 107 | 55 | 55 | 56 | 57 | 50 | 50 | 50 |
|  | 90en | voe | vor | vos | 11* | * 23 | 124 | 1vs | 70 | 70 | $7 \pi$ | 72 | 73 | 78 | 74 |
|  | 95m | 170 | 110 | 1.3 | 125 | 1.7 | 178 | , 2 - | 74 | 70 | 75 | 76 | 77 | 70 | 78 |
|  | som | 117 | 118 | 120 | 122 | 128 | 125 | 126 | az | 80 | 8 | 35 | as | es | Be |
| - | soen | 94 | 95 | 97 | 30 | 100 | 102 | 102 | 56 | 57 | 5 | se | 60 | $\infty$ | 61 |
|  | 90en | 207 | sos | 170 | 112 | 124 | 115 | 176 | 70 | 72 | 72 | 73 | 74 | Ts | 7e |
|  | 95em | *10 | 12 | v** | *v* | v* | *19 | 120 | 75 | 70 | 77 | 78 | 79 | 79 | -0 |
|  | poen | 110 | 2200 | 122 | 123 | v2s | 527 | 127 | as | -4 | es | 5 | 87 | 87 | Es |
| - | Soen | 9s | $\infty$ | $0 *$ | voo | 108 | 103 | 104 | 57 | 58 | 50 | 60 | $6 \pm$ | 6. | 68 |
|  | soen | vos | vง | 112 | 18.4 | 115 | 117 | ข* | 72 | 73 | 70 | 75 | Te | 70 | 75 |
|  | ssem | *13 | , 10* | ve | v* | **9 | *2\% | 427 | 76 | 77 | re | 78 | $\infty$ | er | er |
|  | apen | N20 | $12 \%$ | 123 | 125 | 127 | *2e | 120 | es | es | B | e7 | Ee | Ee | es |
| 10 | soen | 97 | Se | 100 | 102 | 109 | 105 | 106 | Se | 50 | 60 | 6\% | 67 | 62 | 63 |
|  | som | 117 | 112 | 134 | 1.5 | 107 | 110 | 119 | 73 | 73 | 70 | 75 | 7e | 78 | 78 |
|  | ssen | v15 | v1* | 1 17 | 179 | ทマา | 123 | 123 | 75 | re | 5 | mo | ev | er | er |
|  | soun | 122 | 123 | 125 | 127 | *20 | 130 | 130 | es | - | 80 | 88 | ab | -0 | $\infty$ |

## Classification of blood pressure in Girls

Biood Pressuare Levels for Girls by Age and Helght percentile

| Arean | Perop | Sywtotie EPP (mambla) |  |  |  |  |  |  | Dinstathe EPF (mampla) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $\leftarrow$ |  | Percentille of Mellatht $\rightarrow$ |  |  |  |  | $\leqslant$ |  | Percenntile of Melioht $\rightarrow$ |  |  |  |  |
|  |  | 5 sm | nout | 25mb | soth | 7 rats | sorn | 9sen | Sen | 10th | 2 sers | sorts | 75 en | soth | 9sen |
| 8 | soun | 83 | 64 | 3s | B6 | Be | 89 | So | 30 | 30 | 39 | 40 | 41 | 47 | 42 |
|  | sorn | 97 | 97 | Oer | voo | 107 | 100 | 103 | 52 | 53 | 53 | 54 | 55 | ss | se |
|  | soun | 100 | vor | vor | vos | Tos | 10s | 107 | 50 | 57 | 57 | se | 50 | se | eo |
|  | somen | 200 | vos | sor | 1.1 | 123 | 123 | 114 | as | 6s | 53 | 65 | © | 6) | 67 |
| 2 | Som- | 35 | 55 | 87 | \%8 | 80 | 9\% | 97 | 43 | 4 | 4 | 45 | * | 46 | 47 |
|  | soen | se | 00 | 100 | 207 | sos | sos | vos | 57 | se | se | so | ©0 | 6) | en |
|  | 90ut | vos | 100 | vos | vos | vor | voe | 109 | Ex | 03 | er | 63 | ct | as | es |
|  | som | vos | 110 | 171 | 112 | 114 | 115 | 126 | 09 | 09 | 70 | 70 | 70 | 72 | 72 |
| 3 | Scer | Ee | 67 | Qe | 80 | 9 | 92 | 93 | 47 | 4 | $4{ }^{\circ}$ | 49 | so | so | $5 \%$ |
|  | soen | 100 | 100 | 102 | 103 | vos | 106 | 100 | ev | er | 6 | ea | 64 | 64 | es |
|  | asen | 20s | 104 | vos | vor | voe | soes | งข | es | Es | -6 | 67 | ee | 68 | -0 |
|  | soen | 171 | 127 | 123 | 114 | 175 | 176 | 117 | 73 | 73 | 74 | 74 | 75 | 75 | 7e |
| 4 | soun | es | 88 | $\bigcirc$ | 53 | 92 | 94 | Se | 50 | so | 57 | 52 | 52 | 53 | 54 |
|  | som | 107 | vo2 | no3 | 204 | ข0e | T07 | vos | en | 64 | 50 | E | 6. | 67 | 6* |
|  | asen | vos | voe | sa7 | ข08 | 120 | *1* | 1.12 | $\infty$ | 88 | 00 | \% | 77 | 73 | 72 |
|  | som- | 112 | 183 | 124 | 125 | 127 | 218 | 320 | 76 | 7e | 76 | 78 | 73 | 70 | ro |
| 5 | sorm | -9 | \$0 | 97 | 93 | 94 | 35 | ) | 52 | 53 | 59 | 54 | 55 | 55 | 56 |
|  | som- | 109 | $s 00$ | vos | 100 | vor | sos | vos | ©0 | 6\% | ब\% | on | 69 | 09 | T0 |
|  | 9sen | 107 | +07 | voe | 170 | 1.1 | 112 | 123 | 70 | 75 | 71 | 72 | 73 | 73 | 74 |
|  | 9ous | 114 | 384 | 126 | 127 | 210 | 120 | 120 | 78 | 73 | 73 | 78 | eo | 81 | e.t |
| 6 | sour | 97 | 32 | 93 | 54 | 96 | 97 | 38 | 54 | 54 | 55 | Se | 56 | 57 | 58 |
|  | soun | 104 | sos | 108 | Toe | voe | v10 | 117 | E* | *s | 60 | 70 | 70 | 73 | 72 |
|  | asen | vos | vos | 120 | 117 | 123 | 114 | 125 | 72 | 72 | 73 | 34 | 74 | 75 | тe |
|  | sotn | 175 | 120 | 117 | 180 | 220 | 120 | 123 | 80 | mo | 80 | ev | 82 | 03 | 8 |
| 7 | sorn | 83 | 93 | 96 | 0 | 97 | 99 | 3 | 56 | se | Se | 57 | 58 | 58 | 50 |
|  | soun | vos | sor | soe | +00 | 17 | 112 | 173 | 00 | 70 | \% | 77 | 72 | 72 | 73 |
|  | semer | 170 | ** | 112 | 113 | 115 | 175 | Tve | 73 | 74 | 74 | 75 | 76 | 7e | 77 |
|  | som- | 117 | 120 | 119 | 120 | 122 | 123 | 124 | ®\% | es | er | er | 03 | 38 | as |
| * | soth | 3 | 95 | 96 | 98 | 99 | ง00 | 107 | 57 | 57 | 57 | se | 59 | $\infty$ | $\cdots$ |
|  | 30 m | 100 | 100 | 110 | 117 | 113 | 174 | 174 | 77 | 77 | 71 | 72 | 73 | 74 | 74 |
|  | asen | 112 | 112 | 114 | 115 | 176 | 178 | 118 | 75 | 75 | 75 | 7e | 77 | 78 | 78 |
|  | soun | 218 | 120 | 123 | 122 | 123 | 125 | 125 | 83 | 82 | 83 | 8 | 84 | 35 | - |
| - | soun | 56 | 97 | \% | 100 | 102 | 102 | 103 | Se | 58 | 58 | 60 | 60 | es | 61 |
|  | soun | 120 | 120 | 123 | 113 | 124 | 136 | 176 | 72 | 72 | 72 | 73 | 74 | rs | rs |
|  | 9ser. | 114 | 174 | 175 | v17 | ve | T19 | 120 | 76 | 7e | 70 | 75 | 70 | 78 | ro |
|  | soun | 12: | 228 | 123 | 124 | 125 | 127 | 127 | as | 83 | cs | es | es | 66 | 87 |
| 10 | Soms | 9n | 9 | 100 | s00 | 103 | 104 | 105 | so | 50 | so | $\infty$ | 63 | 68 | 62 |
|  | Som | 122 | 122 | 194 | v15 | 12e | 128 | 12* | 73 | 73 | 73 | 74 | 75 | Te | Te |
|  | 9sen | 126 | 116 | 117 | 119 | 120 | 120 | 122 | 77 | 77 | 77 | 78 | 78 | no | eo |
|  | sorn | 123 | 123 | 125 | 126 | 127 | 129 | 129 | E4 | es | 3 | es | ec | 87 | ee |



Management algorithm. BMI, body mass index; BP, blood pressure; Q , every; Rx , prescription; + diet modification and physical activity; $\ddagger$ especially if younger, very high BP, little or no family history, diabetic, or other risk factors. (From National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents.

## When blood pressure should be measured and for who?

- The American Heart Association recommends that children $\mathbf{3}$ yrs or older should have their BP checked during every healthcare episode (the AHA recommends annual BP checks).
- Selected children <3 yrs old should also have their BP checked under special circumstances, including those with a history of prematurity, congenital heart disease, renal disease, solid-organ transplant, cancer, treatment with drugs known to raise BP, other illnesses associated with hypertension (neurofibromatosis, tuberous sclerosis, others), or evidence of increased intracranial pressure.
- The preferred method is by auscultation and a BP cuff appropriate for the size of the child's arm should be used.


## How should blood pressure be measured in children?

- Elevated readings should be confirmed on repeat visits before determining that a child is hypertensive.
- The BP should be measured with the child:
- in the sitting position
- back supported
- feet on ground
- after a period of quiet for at least 5 min.


Following these 7 simple tips
may help you get an accurate
blood pressure reading.Don't Have a Conversation
Talking adds $10-15 \mathrm{mmHg}$
(2) Support Back

Unsupported back adds $5-10 \mathrm{mmHg}$Put Cuff on Bare Arm
Cuff over clothing adds $10-40 \mathrm{mmHg}$
Support Arm at Heart Level Unsupported arm adds 10 mmHg
$\theta$
Empty Bladder
Full bladder adds $10-15 \mathrm{mmHg}$
Keep Legs Uncrossed
Crossing legs adds $5-10 \mathrm{mmHg}$
Support Feet
Unsupported feet add $5-10 \mathrm{mmHg}$

## Proper Cuff Size

- Careful attention to cuff size is necessary to avoid over diagnosis, as a cuff that is too short or narrow artificially increases BP readings.
- A wide variety of bladder sizes should be available in any medical office where children are routinely seen.
- An appropriate sized cuff has an inflatable bladder that is at least $40 \%$ of the arm circumference at a point midway along the upper arm. The inflatable bladder should cover at least two thirds of the upper arm length and 80-100\% of its circumference.



## Ambulatory blood pressure monitoring (ABPM)

Sustained Hypertension


Ambulatory BP

- Ambulatory blood pressure monitoring (ABPM) is a procedure where the child wears a device that records BP frequently, usually every 20-30 min, throughout a 24 hr period while the child goes about usual daily activities, including sleep.
- This allows calculation of the mean daytime BP, sleep BP, and mean BP over 24 hr .
- The physician can also determine the proportion of $B P$ measurements that are in the hypertensive range (BP load) and whether there is an appropriate decrease in BP during sleep (nocturnal dip).
- ABPM is particularly useful in the evaluation for white coat hypertension and may also be useful for determining risk of hypertensive target organ damage, evaluating resistance to pharmacologic therapy, and evaluating patients with hypotensive episodes on antihypertensive medication.
- ABPM is also useful for certain special populations, such as children with chronic kidney disease, kidney transplant, and diabetes mellitus where it may provide important information on cardiovascular risk that cannot be determined as well by office measurements.


## Case 1

- An asymptomatic 16-year-old boy has elevated blood pressure documented on several visits, with an average blood pressure of 144/92 mm Hg.
- His height and weight are above the 97th percentile for age.
- His father has hypertension and takes antihypertensive medication.


## What is the most appropriate approach for this boy?

1. Have the boy return for a repeat blood pressure measurement in 6 months.
2. Provide lifestyle counseling to increase physical activity and lower dietary salt and repeat blood pressure measurement in 6 months.
3. Begin diagnostic evaluation for stage 2 hypertension.
4. Admit to the hospital for immediate blood pressure reduction.

## What is the most appropriate approach for this boy?

1. Have the boy return for a repeat blood pressure measurement in 6 months.
2. Provide lifestyle counseling to increase physical activity and lower dietary salt and repeat blood pressure measurement in 6 months.
3. Begin diagnostic evaluation for stage 2 hypertension.
4. Admit to the hospital for immediate blood pressure reduction.

Joseph TFly!nn, MD / @drjosflynn

## Case 1- Initial Diagnostic Evaluation

- ABPM is done, demonstrating sustained hypertension while awake and asleep, with only 7\% SBP dipping.
- Urinalysis is normal. Creatinine is $0.7 \mathrm{mg} / \mathrm{dL}(62 \mu \mathrm{~mol} / \mathrm{L})$
- Random glucose elevated. Triglycerides and LDL cholesterol elevated. HDL cholesterol low


# The most likely explanation for HTN in this boy ils: 

1. Excess dietary sodium intake
2. Primary hypertension, based on a parent with hypertension.
3. Secondary to pre-diabetes
4. Secondary to obesity

# The most likely explanation for HTN in this boy is: 

1. Excess dietary sodium intake
2. Primary hypertension, based on a parent with hypertension.
3. Secondary to pre-diabetes
4. Secondary to obesity

## Pathophysiology of Obesity HTN



Joseph TFlynn, MD / @drjosflynn

## Case 1 Therapy: Initial Approach

- Weight loss is primary therapy but difficult to achieve
- Increased Physical Activity
- 2017 AAP CPG: "Vigorous" physical activity 3-5 d/wk, 30-60 min/session
- Aerobic exercise or combination of aerobic exercise plus resistance training
- Try to find an activity child is already participating in and intensify it
- Nutritional Counseling
- 2017 AAP CPG: Provide advice on the DASH diet
- DASH eating plan: increased fruits and vegetables, low-fat dairy products $\pm$ sodium restriction (www.dashdiet.org)
- AHA: Reduce sodium intake to 1500-2300 mg/day


## Family-based intervention improves success

## Case 1: Outcome

- He met with a nutritionist who taught him about healthy eating
- Reduced sodium intake
- Cut down on snacks and portion sizes at meals
- His father started taking him to the gym 4 days per week
- He used the treadmill and did weight training
- Over a 2-year period he lost 15 lbs., and his BMI dropped from $>97^{\text {th }}$ percentile to the 93 rd percentile
- His blood pressure fell to the elevated BP range - 120's/70s


## Etiology and Pathophysiology

- Blood pressure is the product of cardiac output (CO) and systemic vascular resistance (SVR).
- An increase in either CO or PVR results in an increase in BP.
- If either of these factors increases while the other decreases, BP may not increase.
- When hypertension is the result of another disease process, it is referred to as secondary hypertension.
- When no identifiable cause can be found, it is referred to as primary hypertension.


## Pathophysiology



## Etiology and Pathophysiology

- Secondary hypertension is most common in infants and younger children.
- It is most often caused by renal abnormalities(90\%); additional etiologies include cardiovascular disease and endocrinopathies.
- Younger age, severely elevated BP, and symptomatic hypertension make a secondary cause of hypertension more likely.
- Many childhood diseases can be responsible for chronic hypertension (Table 1 ) or acute/intermittent hypertension (Table 2 ).
- The most likely cause varies with age.
- Hypertension in the premature infant is sometimes associated with: umbilical artery catheterization, renal artery thrombosis, or bronchopulmonary dysplasia.
- Hypertension during early childhood may be caused by:
renal disease, coarctation of the aorta, endocrine disorders, or medications.


## Causes of Hypertension

| PRIMARY HYPERTENSION | - Essential hypertension <br> - Metabolic syndrome |
| :---: | :---: |
| RENAL CAUSES | - Congenital anomalies (renal dysplasia, obstructive uropathy) <br> - Structural disorders (Wilms tumor, polycystic kidney disease) <br> - Glomerulonephritis <br> - Acquired injury (renal scarring, acute tubular necrosis) |
| ENDOCRINE CAUSES | - Catecholamine-secreting tumors (pheochromocytoma, neuroblastoma) <br> - Hypercortisolism (Cushing syndrome) <br> - Hyperaldosteronism <br> - Hyperthyroidism |
| NEUROLOGICAL CAUSES | - Increased sympathetic activity (stress, anxiety, pain) <br> - Dysautonomia <br> - Increased intracranial pressure |
| VASCULAR CAUSES | - Coarctation of the aorta <br> - Renal artery stenosis <br> - Renal artery embolism (from umbilical artery catheter) <br> - Renal vein thrombosis <br> - Vasculitis |
| OTHER CAUSES | - Obstructive sleep apnea <br> - Medications, illicit drugs |

## Table:1 Conditions Associated With Chronic Hypertension in Children

## Renal

- Recurrent pyelonephritis/renal scarring
- Chronic glomerulonephritis
- Prematurity
- Congenital dysplastic kidney
- Polycystic kidney disease
- Vesicoureteral reflux nephropathy
- Segmental hypoplasia (AskUpmark kidney)
- Obstructive kidney disease
- Renal tumors
- Renal trauma
- Systemic lupus erythematosus (other connective tissue diseases)


## Vascular

- Coarctation of thoracic or abdominal aorta
- Renal artery lesions (stenosis, fibromuscular dysplasia, thrombosis,
- aneurysm)
- Umbilical artery catheterization with thrombus formation
- Neurofibromatosis (intrinsic or extrinsic narrowing for vascular lumen)
- Renal vein thrombosis
- Vasculitis (ANCA associated, polyarteritis nodosa, Takayasu arteritis)
- Arteriovenous shunt
- Williams-Beuren syndrome
- Moyamoya disease


## Endocrine

- Hyperthyroidism
- Congenital adrenal hyperplasia (11 $\beta$ hydroxylase and 17-hydroxylase
- defect)
- Cushing syndrome
- Primary hyperaldosteronism
- Apparent mineralocorticoid excess
- Glucocorticoid remedial aldosteronism (familial aldosteronism type 1)
- Glucocorticoid resistance (Chrousos syndrome)
- Pseudohypoaldosteronism type 2 (Gordon syndrome)
- Pheochromocytoma
- Other neural crest tumors (neuroblastoma, ganglioneuroblastoma, ganglioneuroma)
- Liddle syndrome
- Geller syndrome


## Central Nervous

System

- Intracranial mass
- Hemorrhage
- Residual following brain injury
- Quadriplegia (dysautonomia)
- Sleep disordered breathing


## Table:2 Conditions Associated With Transient or Intermittent Hypertension in Children

## Renal

- Acute postinfectious glomerulonephritis
- Henoch-Schönlein purpura with nephritis
- Hemolytic-uremic syndrome
- Acute kidney injury
- After renal transplantation (immediately and during episodes of rejection)
- Hypervolemia
- Pyelonephritis
- Renal trauma
- Leukemic infiltration of the kidney


## Drugs and Poisons

- Cocaine
- Oral contraceptives
- Sympathomimetic agents
- Amphetamines
- Phencyclidine
- Corticosteroids and adrenocorticotropic hormone
- Cyclosporine, sirolimus, or tacrolimus treatment after transplantation
- Licorice (glycyrrhizic acid)
- Lead, mercury, cadmium, thallium
- Antihypertensive withdrawal (clonidine, methyldopa, propranolol)
- Vitamin D intoxication


## Central and Autonomic Nervous System

- Increased intracranial pressure
- Guillain-Barré syndrome
- Burns
- Familial dysautonomia
- Stevens-Johnson syndrome
- Posterior fossa lesions
- Porphyria
- Poliomyelitis
- Encephalitis
- Spinal cord injury (autonomic storm)

Miscellaneous

- Preeclampsia
- Pain, anxiety
- Hypercalcemia
- After coarctation repair
- White blood cell transfusion
- Extracorporeal membrane oxygenation (ECMO)


## Secondary Hypertension

- Renal disease (e.g., chronic glomerulonephritis, reflux or obstructive nephropathy, hemolytic-uremic syndrome, polycystic kidney disease, congenital anomalies of the kidney and urinary tract) and renovascular hypertension account for approximately $90 \%$ of children with secondary hypertension.
- Renal parenchymal disease and renal artery stenosis lead to water and sodium retention thought to be, in part, secondary to increased renin secretion.
- Coarctation of the aorta must always be considered.
- Several endocrinopathies are associated with hypertension, usually those involving the thyroid, parathyroid, and adrenal glands.
- Systolic hypertension and tachycardia are common in hyperthyroidism; DBP is not usually elevated.
- Hypercalcemia, whether secondary to hyperparathyroidism or other causes, often results in mild elevation in BP because of an increase in vascular tone.
- Adrenocortical disorders (e.g., aldosterone-secreting tumors, sodium-retaining congenital adrenal hyperplasia, Cushing syndrome) may produce hypertension in patients with increased mineralocorticoid secretion.
- It is important to consider conditions associated with real or apparent mineralocorticoid excess and thus a suppressed renin level (with or without hypokalemia) form of secondary hypertension (Table 3 ).
- hypercortisolism $\rightarrow$ stimulation of aldosterone receptors in high concentrations and $\uparrow$ potassium excretion $\rightarrow \uparrow$ blood pressure
- $\uparrow$ Aldosterone $\rightarrow$ 个 Na+ reabsorption and retention $\rightarrow$ water retention $\rightarrow$ hypertension


## Table:3 Clinical Findings in Patients With Mineralocorticoid Excess

| CONDITION | CLINICAL PRESENTATION |
| :--- | :--- |
| - CAH: $11 \beta$-hydroxylase deficiency | Early growth spurt initially, then short adult stature, advanced bone age, <br> premature adrenarche, acne, precocious puberty in males, <br> amenorrhea/ hirsutism/virilism in females (autosomal recessive) |
| - CAH: $17 \alpha$-hydroxylase deficiency | Pseudohermaphroditism (male), sexual infantilism (female) (autosomal <br> recessive) |
| - Apparent mineralocorticoid excess | Growth retardation/short stature, nephrocalcinosis (autosomal recessive) |
| - Liddle syndrome | Severe hypertension, hypokalemia, and metabolic alkalosis, muscle weakness <br> (autosomal dominant) |
| - Geller syndrome |  |
| (exacerbated by pregnancy) | Early onset of hypertension (before age 20 yr), exacerbated in pregnancy |
| -Glucocorticoid-remediable aldosteronism (GRA) <br> (familial aldosteronism type 1) | Early onset of hypertension, presence of family history of mortality or <br> morbidity from early hemorrhagic stroke (autosomal dominant) |
| -Pseudohypoaldosteronism type 2 <br> (Gordon syndrome) | Short stature, hyperkalemic and hyperchloremic metabolic acidosis, borderline <br> blood pressure (autosomal dominant)) |
| -Glucocorticoid resistance (children) (Chrousos <br> syndrome) | Ambiguous genitalia, precocious puberty; women may have androgen excess: <br> acne, excessive hair, oligo/anovulation, infertility (familial or sporadic) |

## Secondary Hypertension

- Pheochromocytomas are catecholamine-secreting tumors that give rise to hypertension because of the cardiac and peripheral vascular effects of epinephrine and norepinephrine.
- Children with pheochromocytoma usually have sustained rather than intermittent or exercise-induced hypertension.
- Pheochromocytoma develops in approximately $5 \%$ of patients with neurofibromatosis and can also be seen in certain genetic disorders such as von Hippel-Lindau disease.
- Rarely, secondary hypertension can be caused by pseudohyperaldosteronism, which leads to elevated BP in the face of a suppressed renin level. Such disorders include Liddle syndrome, apparent mineralocorticoid excess, and glucocorticoid-remediable aldosteronism.
- Altered sympathetic tone can be responsible for acute or intermittent elevation of BP in children with GuillainBarré syndrome, poliomyelitis, burns, and Stevens- Johnson syndrome. Intracranial lesions also affect sympathetic outflow from the central nervous system.


## Secondary Hypertension

- A number of drugs of abuse , therapeutic agents, and toxins may cause hypertension.
- Cocaine may provoke a rapid increase in BP and can result in seizures or intracranial hemorrhage.
- Phencyclidine causes transient hypertension that may become persistent in chronic abusers.
- Tobacco use may also increase BP.
- Sympathomimetic agents used as nasal decongestants, appetite suppressants, and stimulants for attention-deficit disorder produce peripheral vasoconstriction and varying degrees of cardiac stimulation. Individuals vary in their susceptibility to these effects.
- Oral contraceptives should be suspected as a contributor to elevated BP in adolescent girls, although the incidence is lower with the use of low-estrogen preparations.
- Immunosuppressant agents such as cyclosporine and tacrolimus cause hypertension in organ transplant recipients, and the effect is exacerbated by the co-administration of corticosteroids.
- BP may be elevated in patients with poisoning by a heavy metal (lead, cadmium, mercury).


## Primary Hypertension

- In older school-age children and adolescents, primary hypertension becomes increasingly common. These patients often are overweight, have a strong family history of hypertension, and have BP values at, or only slightly above, the $95^{\text {th }}$ percentile for age.
- Isolated systolic hypertension is also more consistent with primary hypertension, whereas diastolic hypertension may suggest a secondary cause.
- The cause of primary hypertension is likely to be multifactorial; obesity, genetic alterations in calcium and sodium transport, vascular smooth muscle reactivity, the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system over activity, and insulin resistance have been implicated in this disorder.
- Elevated uric acid levels may play a role in the pathophysiology of primary hypertension, and proof-of-concept studies have confirmed that lowering of uric acid levels results in lower BP in overweight youth with hypertension or prehypertension.


## Primary Hypertension

- Some children and adolescents demonstrate salt-sensitive hypertension , a factor that is ameliorated with weight loss and sodium restriction.
- Normotensive children of hypertensive parents may show abnormal physiologic responses that are similar to those of their parents. When subjected to stress or competitive tasks, the offspring of hypertensive adults, as a group, respond with greater increases in heart rate and BP than do children of normotensive parents.
- Similarly, some children of hypertensive parents may excrete higher levels of urinary catecholamine metabolites or may respond to sodium loading with greater weight gain and increases in BP than do those without a family history of hypertension.
- The abnormal responses in children with affected parents tend to be greater in the black population than among white individuals.


## Clinical Manifestations

- Children and adolescents with primary hypertension are usually asymptomatic.
- the BP elevation is usually mild and is detected during a routine examination or evaluation before athletic participation. These children may also be obese.
- Children with secondary hypertension can have BP elevations ranging from mild to severe.
- Unless the BP has been sustained or is rising rapidly, hypertension does not usually produce symptoms.
- Therefore, clinical manifestations may instead reflect the underlying disease process, such as growth failure in children with CKD.
- Children and adolescents with acute severe hypertension, in contrast, present with BP elevation well above stage $\mathbf{2}$ ( $\mathbf{~} \mathbf{9 9}{ }^{\text {th }} \mathbf{+ 5 m m h g}$ ) hypertension and severe symptoms that may represent acute target-organ injury.
- Subclinical hypertensive target-organ injury is a common clinical manifestation in children with primary hypertension. Using echocardiography with pediatric normative data, left ventricular hypertrophy is detected in up to $40 \%$ of hypertensive children.
- Other markers of target-organ damage that have been demonstrated in hypertensive children include: hypertensive retinopathy, increased carotid intima-to-media thickness, and increased vascular stiffness.
- Children with prehypertension also have evidence of target-organ damage, often at a magnitude intermediate between that of normotensive and hypertensive children.


## Goals of the evaluation

- Distinguish between primary and secondary HTN
- Uncovering potential underlying causes of the hypertension
- Evaluating for comorbidities
- Identify patients for whom antihypertensive drug therapy is warranted
- Screening for evidence of target organ damage
- The extent of the evaluation for underlying causes of hypertension depends on the type of hypertension that is suspected.


## History

## Age

- Secondary HTN is more likely in younger children, especially those less than 6 years of age. While older children and adolescents are more likely to have primary HTN.

Onset

- Acute, severe onset is caused by drug toxicity , coarctation of aorta or hypertensive encephalopathy.

Associated symptoms :

* Abdominal pain, dysuria, frequency, nocturia, enuresis, hematuria, and edema may indicate a renal cause

In infants, growth failure, irritability, and feeding problems may be symptoms of HTN
Joint pain or swelling may be due to collagen vascular diseases
Weight loss, sweating, and pallor may be due to a catecholamine- secreting tumor.

## History

Muscle cramps or weakness and constipation may be seen with the hypokalemia associated with hyperaldosteronism

- Menstrual disorders, hirsutism, and virilization may indicate forms of congenital adrenal hyperplasia (CAH) associated with HTN
* A neonatal history of umbilical artery line placement can result in renal artery embolization, leading to HTN
* History of prolonged loud snoring may identify sleep- related causes of HTN
* Hypertensive encephalopathy may occur as nausea, vomiting, altered mental status, visual disturbances, seizures, or stroke.
*Intermittent HTN may be present in patients with autonomic instability (e.g., Guillain-Barré syndrome, burns, poliomyelitis, Stevens-Johnson syndrome, porphyria)
*Family history of hypertension , early deaths or renal diseases .
History of drug intake


## History in the child or adolescent with elevated blood pressure

| History | Possible cause of hypertension |
| :--- | :--- |
| CNS: Head trauma, headache, visual disturbance lethargy. <br> seizures, tremors morning vomiting | Elevated intracranial pressure |
| Hearing: Hearing loss | Renal disease (ie, Alport syndrome) |
|  | Lead poisoning |
| Cardiovascular: Palpitations, irregular pulse | Catecholamine excess |
| Renal: Edema, history of UTI or unexplained fever, abnormal <br> urine color, enuresis, flank pain, dysuria | Renal disease or condition (eg. pyelonephritis, acute <br> glomerulonephritis, acute kidney injury. and chronic <br> kidney disease) |
| Skin: Rash, sweating pallor | Catecholamine excess |
|  | Thyroid dysfunction |
| Renal vasculitis |  |
| Recent medical history: Recent pharyngitis or | Post-infectious glomerulonephritis |
| impetigo, exposure to sources of enterohemorrhagic E. coll | Hemolytic uremic syndrome |
| Medications: Sympathomimetics oral contraceptives, <br> corticosteroids | Side effect of medication |
| Substance use: Cocaine, amphetamines anabolic steroids <br> phencyclidine, ephedra- containing alternative medications <br> caffeine | Drug-mediated effects |
| Family history: Hypertension early MI. diabetes, stroke | Essential hypertension |
| Sexual history: Postmenarchal female actively engaged in <br> sexual intercourse | Preeclampsia |
| Neonatal history: Use of umbilical artery catheters | Renovascular hypertension |
| Growth history: Excessive weight gain or loss, change in <br> growth percentiles | Obesity, thyroid dysfunction |
| Dietary history: Types and amount of food ingested; salt <br> craving | Obesity, essential hypertension |
| Social history: Stress factors at home and school | Stress |

## Physical Examination :

| Physical Examination Finding | Possible Etiology |
| :--- | :--- |
| General |  |
| Obesity | Essential Hypertension |
| Truncal Obesity | Cushing syndrome, Corticosteroid therapy |
| Growth Retardation | Chronic Kidney Disease |
| Vital Signs | Catecholamine excess (PCC or <br> neuroblastoma) or Hyperthyroidism |
| Tachycardia | If upper extremity BP> Lower extremity <br> BP, coarctation of aorta |
| BP difference in Extremeties | Williams Syndrome |
| Head and Neck | Cushing Syndrome, Corticosteroid therapy |
| Elfin face | Hyperthyroidism |
| Moon Face | Turner Syndrome |
| Thyroid enlargement or goiter | Sleep-disordered breathing, Sleep apnea |
| Webbed Neck |  |
| Tonsillar Hypertrophy |  |


| Physical Examination Finding |  |  |  | Possible Etiology |
| :--- | :--- | :---: | :---: | :---: |
| Eye |  |  |  |  |
| Retinal changes | Suggest severe hypertension and secondary etiology |  |  |  |
| Papilledema | Increase intracranial pressure |  |  |  |
| Skin |  |  |  |  |
|  | Pallor, flushing |  |  |  |
| Acne, hirsutism, striae | Catecholamine excess (PCC and neuroblastoma) |  |  |  |
|  | Café-au-lait spots and/or neurofibromas |  |  |  |
| Ash leaf spots and/or adenoma sebaceum | Cushing syndrome, corticosteroid therapy |  |  |  |
| Rash | Tuberous sclerosis |  |  |  |
|  | Acanthosis nigricans |  |  |  |
| Chest | Lupus nephritis, Henoch-Schönlein purpura (IgA vasculitis) |  |  |  |
| Widely spaced nipples | Type 2 diabetes |  |  |  |
| Murmur | Turner syndrome |  |  |  |
|  | Apical heave |  |  |  |
| Abdomen | Coarctation of the aorta |  |  |  |
| Abdominal bruit | Left ventricular hypertrophy |  |  |  |
| Mass | Renovascular disease |  |  |  |

## Physical Examination :

| Physical Examination Finding | Possible Etiology |
| :--- | :--- |
| Extremities |  |
| Traction/casts | Orthopedic Manipulation |
| Asymmetry of limbs | Beckwith-Weidemann syndrome |
| Arthritis | Henoch-Schonlein purpura (igA vasculitis), Collagen vascular <br> disease (systemic lupus erythematous) |
| Neurologic |  |
| Muscle Weakness | Liddle syndrome, hyperaldosteronism |
| Diminished pain response | Familial dysautonomia |
| Genitalia |  |
| Ambiguous/ virilization | Adrenal Hyperplasia |
| Advanced puberty | Intracranial tumors |

## Investigations

## Initial evaluation

- CBC
- BUN/ creatinine
- Electrolytes, calcium
- Urinalysis
- Renal ultrasound


## Consider

- Evaluation for co-morbidity
- -Fasting lipid panel
- -Fasting glucose
- -Polysomnography (sleep study)
- Evaluation for target-organ damage
- -Echocardiogram (LVH)
- -Retinal exam


## Investigations

## Further evaluation as indicated

(stage 2, prepubertal age, findings specific to underlying condition)
(1)Free T4, TSH
(1)Ambulatory BP monitoring
(1)Plasma renin
(10Renovascular imaging
(10)Plasma and urine catecholamines
(10)Plasma and urinary steroids
(DU) Urine pregnancy test (if suspected)
(10Cranial imaging (should be considered to rule out an intracranial mass in children with H and P indicating raised ICP)

## Case 2

- 5 y/o boy, presents for routine well-child visit
- Not seen in > 2 years.
- BP's 137/85, 129/90, confirmed by you with manual sphygnomanometer
- What's the next step ?


## Case 2 - DIAGNOSIS

## - History

- Has had intermittent headaches without any accompanying symptoms
- Was a term baby with no neonatal complications and no prior hospitalizations or surgeries
- No medication or supplement use
- FH of HTN affecting father, 3 of 4 grandparents, mother has T2DM. No FH of kidney disease


## - Physical examination

- Normal appearance
- Weight 33.9 kg (>97\%tile)
- Height 118.1 cm (50\%tile)
- BMI 24 kg/m2 (>97\%tile)
- HEENT, cardiac, abdominal, GU exams all normal
- Referred to HTN Clinic
- Referral BP's 137/85, 129/90
- UE BP's in our office: 132/92, 128/88, 140/89
- Mean BP: 133/80
- 90th percentile: 107/68
- 95th percentile: 111/71
- 95th percentile $+12 \mathrm{mmHg}: 123 / 83$
- LE BP's done: 102/55, 108/70
- Investigations
- Labs, imaging studies ordered
- Started on propranolol
- Normal UA, creatinine, electrolytes, elevated renin
- Echocardiogram: structurally normal heart with LVH
- Complete kidney US: kidneys of normal appearance and size bilaterally
- CT- angiogram performed


## Case 2 - CT ANGIOGRAM



## Relevant Guidance from the 2017 AAP CPG

- 16. Doppler renal ultrasonography may be used as a noninvasive screening study for the evaluation of possible RAS in normal wt children and adolescents $\geq 8 \mathrm{y}$ of age who are suspected of having renovascular HTN and who will cooperate with the procedure.
- C, moderate
- 17. In children and adolescents suspected of having RAS, either CTA or MRA may be performed as noninvasive imaging studies.
- D, weak
- 11. Children and adolescents $\geq 6 y$ of age do not require an extensive evaluation for secondary causes of HTN if they have:
- -a positive family history of HTN
- -are overweight or obese
- -and/or do not have history or physical examination findings suggestive of a secondary cause of HTN.
- C, Moderate


## Distribution of HTN Causes by Age



## Case 2: Follow-up

- Propranolol and amlodipine needed to control BP
- Repeat echo 6 mo later - improved LVH
- Followed with repeat kidney ultrasounds to monitor kidney growth
- Underwent surgical reconstruction of abdominal aorta and reimplantation of renal arteries bilaterally
- Now off antihypertensive medications but still being closely followed


## Prevention

- Prevention of high BP may be viewed as part of the prevention of cardiovascular disease and stroke, the leading cause of death in adults in the United States.
- Population approaches to prevention of primary hypertension include :
- A reduction in obesity
- Reduced sodium intake
- an increase in physical activity through school- and community-based programs.


## Treatment

- Children + Asymptomatic mild hypertension without evidence of target-organ damage:

1. Lifestyle modification
2. Dietary changes:

DASH diet (diet increased in fresh fruits, fresh vegetables, fiber, and nonfat dairy and reduced in sodium)
3. Regular exercise:

30-60 min on most days

## Treatment

## Indications for pharmacologic therapy include

symptomatic hypertension
stage 2 hypertension without a modifiable risk factor
hypertension in patients with comorbidities such as diabetes (types 1 and 2) or CKD persistent hypertension despite nonpharmacologic measures.

* Acceptable initial agents for use in children:

Angiotensin-converting enzyme inhibitors (ACEIs)
Angiotensin receptor blockers (ARBs)
Thiazide diuretics
Calcium channel blockers
The choice of antihypertensive agent for a patient should be tailored to the etiology of that patient's hypertension whenever possible.


FIG. 472.3 Stepped-care approach to antihypertensive therapy in children and adolescents. BP, Blood pressure. (From Flynn JT, Daniels SR: Pharmacologic treatment of hypertension in children and adolescents, J Pediatr 149:746-754, 2006, Fig 2, p

| CLASS | DRUG | STARTING DOSE | INTERVAL | MAXIMUM DOSE* |
| :---: | :---: | :---: | :---: | :---: |
| Aldosterone receptor antagonist | Eplerenone | $25 \mathrm{mg} /$ day | qd-bid | $100 \mathrm{mg} /$ day |
|  | Spironolactone ${ }^{\dagger}$ | $1 \mathrm{mg} / \mathrm{kg} /$ day | qd-bid | $3.3 \mathrm{mg} / \mathrm{kg} /$ day up to $100 \mathrm{mg} /$ day |
| Angiotensin-converting enzyme inhibitors | Benazepril $\dagger$ | $0.2 \mathrm{mg} / \mathrm{kg} /$ day up to 10 $\mathrm{mg} /$ day | qd | $0.6 \mathrm{mg} / \mathrm{kg} /$ day up to $40 \mathrm{mg} /$ day |
|  | Captopril $\dagger$ | $0.5 \mathrm{mg} / \mathrm{kg} /$ dose ( $0.05 \mathrm{mg} / \mathrm{kg} /$ dose in infants) | tid | $6 \mathrm{mg} / \mathrm{kg} /$ day up to 450 mg/day |
|  | Enalapril $\dagger$ | $0.08 \mathrm{mg} / \mathrm{kg} /$ day | qd | $0.6 \mathrm{mg} / \mathrm{kg} /$ day up to $40 \mathrm{mg} /$ day |
|  | Fosinopril | $0.1 \mathrm{mg} / \mathrm{kg} /$ day up to 10 mg/day | qd | $0.6 \mathrm{mg} / \mathrm{kg} /$ day up to $40 \mathrm{mg} /$ day |
|  | Lisinopril $\dagger$ | $0.07 \mathrm{mg} / \mathrm{kg} /$ day up to 5 $\mathrm{mg} /$ day | qd | $0.6 \mathrm{mg} / \mathrm{kg} /$ day up to $40 \mathrm{mg} /$ day $40 \mathrm{mg} /$ day |
|  | Quinapril | 5-10 mg/day | qd | $80 \mathrm{mg} /$ day |
|  | Ramipril | $1.6 \mathrm{mg} / \mathrm{m}^{2} /$ day | qd | $6 \mathrm{mg} / \mathrm{m}^{2}$ /day up to 10 mg /day |
| Angiotensin receptor blockers | Candesartan | $\begin{aligned} & 1-6 \mathrm{yr}: 0.2 \mathrm{mg} / \mathrm{kg} / \text { day } \\ & 6-17 \mathrm{yr} \\ & <50 \mathrm{~kg} 4-8 \mathrm{mg} \mathrm{qd} \\ & >50 \mathrm{~kg} 8-16 \mathrm{mg} \text { qd } \end{aligned}$ | qd | $\begin{aligned} & 1-6 \mathrm{yr}: 0.4 \mathrm{mg} / \mathrm{kg} \\ & \text { up to } 4 \mathrm{mg} / \mathrm{day} \\ & 6-17 \mathrm{yr}: \\ & <50 \mathrm{~kg}: 16 \mathrm{mg} \mathrm{qd} \\ & >50 \mathrm{~kg}: 32 \mathrm{mg} \mathrm{gd} \end{aligned}$ |
|  | Losartan $\dagger$ | $0.75 \mathrm{mg} / \mathrm{kg} /$ day up to 50 $\mathrm{mg} /$ day | qd | $1.4 \mathrm{mg} / \mathrm{kg} /$ day up to $100 \mathrm{mg} /$ day |
|  | Olmesartan | 20 to $<35 \mathrm{~kg} 10 \mathrm{mg}$ qd; $\geq 35 \mathrm{~kg} 20 \mathrm{mg}$ qd | qd | 20 to < 35 kg : 20 mg qd <br> $\geq 35 \mathrm{~kg}: 40 \mathrm{mg}$ qd |
|  | Valsartan $\dagger$ | 6-17 yr: $1.3 \mathrm{mg} / \mathrm{kg} /$ day up to $40 \mathrm{mg} /$ day | qd | 6-17 yr: 2.7 <br> $\mathrm{mg} / \mathrm{kg} /$ day up to 160 mg/day |
| $\alpha$ - and $\beta$-Adrenergic antagonists | Labetalol $\dagger$ | 2-3 mg/kg/day | bid | $10-12 \mathrm{mg} / \mathrm{kg} /$ day up to $1.2 \mathrm{~g} / \text { day }$ |
|  | Carvedilol | $0.1 \mathrm{mg} / \mathrm{kg} /$ dose up to 6.25 mg bid | bid | $\begin{aligned} & \hline 0.5 \mathrm{mg} / \mathrm{kg} / \text { dose up to } \\ & 25 \mathrm{mg} \text { bid } \\ & \hline \end{aligned}$ |
| $\beta$-adrenergic antagonists | Atenolol $\dagger$ | $0.5-1 \mathrm{mg} / \mathrm{kg} /$ day | qd-bid | $\begin{aligned} & \hline 2 \mathrm{mg} / \mathrm{kg} / \text { day up to } 100 \\ & \mathrm{mg} / \mathrm{day} \end{aligned}$ |
|  | Bisoprolol/HCTZ | 2.5/6.25 mg/day | qd | $10 / 6.25 \mathrm{mg}$ /day |
|  | Metoprolol | $1-2 \mathrm{mg} / \mathrm{kg} /$ day | bid | $\begin{aligned} & \hline 6 \mathrm{mg} / \mathrm{kg} / \text { day up to } 200 \\ & \mathrm{mg} / \text { day } \end{aligned}$ |
|  | Propranolol | $1 \mathrm{mg} / \mathrm{kg} /$ day | bid-tid | $8 \mathrm{mg} / \mathrm{kg} /$ day up to 640 mg/day |
|  |  |  |  |  |

## Treatment

| Calcium channel blockers | Amlodipine $\dagger$ | $1-5$ yr: $0.1 \mathrm{mg} / \mathrm{kg} /$ day $\geq 6$ yr: $2.5 \mathrm{mg} /$ day | qd | $1-5 \mathrm{yr}: 0.6$ $\mathrm{mg} / \mathrm{kg} /$ day up to 5 mg /day $\geq 6 \mathrm{yr}: 10 \mathrm{mg} /$ day |
| :---: | :---: | :---: | :---: | :---: |
|  | Felodipine | $2.5 \mathrm{mg} /$ day | qd | $10 \mathrm{mg} /$ day |
|  | Isradipine ${ }^{\dagger}$ | 0.05-0.15 mg/kg/dose | tid-qid | $0.6 \mathrm{mg} / \mathrm{kg} /$ day up to $10 \mathrm{mg} /$ day |
|  | Extended-release nifedipine | 0.2-0.5 mg/kg/day | qd-bid | $3 \mathrm{mg} / \mathrm{kg} /$ day up to 120 mg/day |
| Central $\alpha$-agonist | Clonidine ${ }^{\dagger}$ | $5-10 \mu \mathrm{~g} / \mathrm{kg} /$ day | bid-tid | $25 \mu \mathrm{~g} / \mathrm{kg} /$ day up to 0.9 mg/day |
| Diuretics | Amiloride | $5-10 \mathrm{mg} /$ day | qd | $20 \mathrm{mg} /$ day |
|  | Chlorthalidone | $0.3 \mathrm{mg} / \mathrm{kg} /$ day | qd | $2 \mathrm{mg} / \mathrm{kg} /$ day up to 50 mg/day |
|  | Chlorothiazide | $10 \mathrm{mg} / \mathrm{kg} /$ day | bid | $20 \mathrm{mg} / \mathrm{kg} /$ day up to $375 \mathrm{mg} /$ day |
|  | Furosemide | 0.5-2.0 mg/kg/dose | qd-bid | $6 \mathrm{mg} / \mathrm{kg} /$ day |
|  | HCTZ | $0.5-1 \mathrm{mg} / \mathrm{kg} /$ day | qd | $3 \mathrm{mg} / \mathrm{kg} /$ day up to $37.5 \mathrm{mg} /$ day |
| Vasodilators | Hydralazine | $0.25 \mathrm{mg} / \mathrm{kg} /$ dose | tid-qid | $7.5 \mathrm{mg} / \mathrm{kg} /$ day up to $200 \mathrm{mg} /$ day |
|  | Minoxidil | 0.1-0.2 mg/kg/day | bid-tid | $1 \mathrm{mg} / \mathrm{kg} /$ day up to 50 mg/day |

* The maximum recommended adult dose should never be exceeded.
${ }^{\dagger}$ Information on preparation of a stable extemporaneous suspension is available for these agents. bid, Twice daily; HCTZ, hydrochlorothiazide; qd, once daily; qid, 4 times daily; tid, 3 times daily.
Adapted from Flynn JT: Management of hypertension in the young: role of antihypertensive medications, J Cardiovasc Pharmacol 58(2)111-120, 2011.


## Treatment

- There have been changes in the recommended BP goals for treatment of hypertension in children and adolescents.
- Data from the SPRINT (SBP intervention) trial group suggests that stricter goals (SBP goal of 120 vs 140 mm Hg ) improve cardiovascular outcomes in adults.
- In children with CKD, the ESCAPE (Effects of Strict BP Control and Angiotensin-Converting Enzyme Inhibition on the Progress of Chronic Renal Failure in Pediatric Patients) trial group showed slower progression of CKD if the 24 hr MAPs were kept below the 50th percentile on ABPM compared to the 50th-95th percentile.
- It is now recommended that treatment achieve BP such as headache, dizziness, or nausea/vomiting (hypertensive urgency ) and in more severe cases, retinopathy, encephalopathy, cardiac failure, renal injury, and seizures(hypertensive emergency)


## Hypertensive Encephalopathy (generalized or posterior reversible encephalopathy syndrome)

- It is suggested by the presence of

1. Headache
2. Vomiting
3. Temperature elevation
4. Visual disturbances
5. Ataxia
6. Depressed level of consciousness

- it is one of the more common presentations of acute severe hypertension in children and adolescents.


FIG. 472.4 Magnetic resonance image of brain of a 6 yr old boy with end-stage renal disease and hypertensive encephalopathy (i.e., posterior reversible

## Treatment

## Manifest of Acute severe hypertension

- Decreased vision (cortical blindness)
- Papilledema
- Congestive heart failure
- Accelerated deterioration of renal function

Acute severe hypertension and life-threatening symptoms,

- Intensive care unit (ICU) admission
- Intravenous (IV) drug infusion
- Arterial lines should be used for continuous BP monitoring
- It is indicated so that decreases in BP can be carefully monitored and titrated


## Drug of choice

- labetalol, nicardipine, and sodium nitroprusside.
- Why ?

1. Rapid a reduction in $B P$ may interfere
2. Adequate organ perfusion

## Antihypertensive Drugs for Management of Severe Hypertension in Children Age 1-17 yr.

| DRUG | CLASS | DOSE ROUTE COMMENTS |  |  |
| :---: | :---: | :---: | :---: | :---: |
| USEFUL FOR SEVERELY HYPERTENSIVE PATIENTS WITH LIFE-THREATENING SYMPTOMS |  |  |  |  |
| Esmolol | $\beta$ Adrenergic blocker | $100-500 \mu \mathrm{~g} / \mathrm{kg} / \mathrm{min}$ | $\begin{aligned} & \hline \text { IV } \\ & \text { infusion } \end{aligned}$ | Very short acting - constant infusion preferred; may cause profound bradycardia |
| Hydralazine | Direct vasodilator | 0.2-0.4 mg/kg/dose | IV, IM | Should be given every 4 hr when given IV bolus |
| Labetalol | $\alpha$ - and $\beta$ Adrenergic blocker | Bolus: 0.20-1.0 $\mathrm{mg} / \mathrm{kg} /$ dose, up to $40 \mathrm{mg} /$ dose <br> Infusion: 0.25-3.0 $\mathrm{mg} / \mathrm{kg} / \mathrm{hr}$ | IV bolus or infusion | Asthma and overt heart failure are relative contraindications. |
| Nicardipine | Calcium channel blocker | Bolus: $30 \mu \mathrm{~g} / \mathrm{kg}$ up to $2 \mathrm{mg} /$ dose Infusion: 0.5-4 $\mu \mathrm{g} / \mathrm{kg} / \mathrm{min}$ | IV bolus or infusion | May cause reflex tachycardia |
| $\begin{aligned} & \hline \text { Sodium } \\ & \text { nitroprusside } \end{aligned}$ | Direct vasodilator | $0.5-10 \mu \mathrm{~g} / \mathrm{kg} / \mathrm{min}$ | IV infusion | Monitor cyanide levels with prolonged ( $>72 \mathrm{hr}$ ) use or in renal failure; or co-administer with sodium thiosulfate. |
| USEFUL FOR SEVERELY HYPERTENSIVE PATIENTS WITH LESS SIGNIFICANT SYMPTOMS |  |  |  |  |
| Clonidine | Central $\alpha$ agonist | $0.05-0.1 \mathrm{mg} /$ dose, may be repeated up to 0.8 mg total dose | PO | Side effects include dry mouth and drowsiness. |
| Fenoldopam | Dopamine receptor agonist | 0.2-0.8 $\mu \mathrm{g} / \mathrm{kg} / \mathrm{min}$ | IV infusion | Produced modest reductions in blood pressure in a pediatric clinical trial in patients up to age 12 yr |
| Hydralazine | Direct vasodilator | $0.25 \mathrm{mg} / \mathrm{kg} /$ dose, up to $25 \mathrm{mg} /$ dose | PO | Extemporaneous suspension stable for only 1 wk |
| Isradipine | Calcium channel blocker | $0.05-0.15 \mathrm{mg} / \mathrm{kg} /$ dose, up to $5 \mathrm{mg} /$ dose | PO | Stable suspension can be compounded. |
| Minoxidil | Direct <br> vasodilator | $0.1-0.2 \mathrm{mg} / \mathrm{kg} /$ dose, up to $10 \mathrm{mg} /$ dose | PO | Most potent oral vasodilator; long acting |

ACE, Angiotensin-converting enzyme; IM, intramuscular; IV, intravenous; PO, oral.
Adapted from Flynn JT, Tullus K: Correction to severe hypertension in children and adolescents: pathophysiology and treatment, Pediatr Nephrol 27(3):503-504, 2012.

## Treatment

- In general, BP should be reduced by no more than $25 \%$ of the planned reduction over the $1^{\text {st }} 8 \mathrm{hr}$., with a gradual normalization of BPs over next $24-48 \mathrm{hr}$.
- For patients with less severe symptoms, such as headache or nausea/vomiting,

1. Oral medications such as Clonidine or Isradipine can be used
2. Short-acting IV medications such as hydralazine or labetalol are

## Treatment



## Case 3: Initial evaluation

- A14-year-old soccer player referred for evaluation of elevated blood pressure detected at a pre-sports participation screening at her school.
- Blood pressures obtained at the screening ranged from $137-149 / 75-80 \mathrm{mmHg}$.
- Repeat office BP's are similar to the readings at the sports physical
- She denies any symptoms of hypertension.
- She is at the 50th percentile for height and weight and has no other chronic health problems or abnormal physical examination findings. Both parents have hypertension.


## Next step should be:

1. Start hydrochlorothiazide 25 mg daily
2. Refer to IR for arteriogram
3. Perform 24 -hr ambulatory BP monitoring
4. Request that the school nurse check her BP daily for the next 10 days

## Next step should be:

## 1. Start hydrochlorothiazide 25 mg daily

2. Refer to IR for arteriogram
3. Perform 24-hr ambulatory BP monitoring
4. Request that the school nurse check her BP daily for the next 10 days

## Further Evaluation

- 24-hr ABPM demonstrates sustained ambulatory hypertension with normal nocturnal dipping
- Urinalysis, electrolytes, BUN and Cr are normal.
- Fasting lipids: total cholesterol 195, LDL cholesterol 90, HDL cholesterol 52, triglycerides 165.


## What is your diagnosis?

1. Metabolic Syndrome
2. Primary hypertension
3. Renal artery stenosis
4. Polycystic kidney disease

## What is your diagnosis?

## 1. Metabolic Syndrome

2. Primary hypertension
3. Renal artery stenosis
4. Polycystic kidney disease

Joseph T Flynn, MD/ @drjosflynn

## Goal for Antihypertensive Treatment in Children

- 19. In children and adolescents diagnosed with HTN, the treatment goal with nonpharmacologic and pharmacologic therapy should be a reduction in SBP and DBP to $<90$ th percentile and $<130 / 80 \mathrm{~mm} \mathrm{Hg}$ in adolescents $\geq 13$ years old.
- C, moderate
- 23-2. Children or adolescents with both CKD and HTN should be treated to lower 24-hr MAP <50th percentile by ABPM
- B, strong


## Sports Participation and Hypertension

- 28. Children and adolescents with HTN may participate in competitive sports once hypertensive target organ effects and cardiovascular risk have been assessed.
- C, moderate
- 29. Children and adolescents with HTN should receive treatment to lower BP below stage 2 thresholds before participation in competitive sports.
- C, moderate

Seattle Children's
UW Medicine

## Classification of Various Sports



Joseph TFlynn, MD/ @drjosflynn

## Case 3: Outcome

- Clinic BP readings remained at stage 2 HTN level
- Allowed to participate in light workouts with team, but restricted from competition
- Echocardiogram done - normal EF, mild concentric LVH
- Started on therapy with amlodipine 5 mg daily
- Dose increase to 10 mg based on home BP readings
- Follow-up clinic BP 132/78
- Allowed to compete in soccer


## Resources

- 2017 AAP CPG
- https://pediatrics.aappublications.org/content/140/3/e20171904.Iong
- NEJM video on BP measurement
- https://www.nejm.org/doi/full/10.1056/NEJMvcm0800157
- 2014AHAPediatric ABPM statement
- https://www.ahajoumals.org/doi/10.1161/HYP. 0000000000000007

Joseph TFly!nn, MD / @drjosflynn


Resources:
Nelson Textbook of Pediatrics
$21^{\text {st }}$ Edition

